Appili Therapeutics' Licensing Partner Gets FDA Approval for Metronidazole Oral Suspension
25 Septiembre 2023 - 7:44AM
Noticias Dow Jones
By Robb M. Stewart
Appili Therapeutics expects to receive milestone payments and
royalties from Saptalis Pharmaceuticals after the U.S. Food and
Drug Administration approved the liquid oral reformulation of the
antibiotic metronidazole, which has been licensed to Saptalis for
commercialization in the U.S. and other select markets.
The biopharmaceutical company said Saptalis received FDA
approval for ATI-1501, metronidazole oral suspension 500 milligram.
The FDA also approved Likmez as the brand name for ATI-1501.
Don Cilla, president and chief executive of Appili, said the
approval of Likmez shortly after patent coverage was secured
through 2039 demonstrates the company's ability to identify
promising opportunities and develop and monetize them for the
benefit of patients and shareholders.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
September 25, 2023 08:29 ET (12:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Appili Therapeutics (TSX:APLI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Appili Therapeutics (TSX:APLI)
Gráfica de Acción Histórica
De May 2023 a May 2024
